HC Wainwright Equities Analysts Reduce Earnings Estimates for X4 Pharmaceuticals, Inc. (NASDAQ:XFOR)

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) – Investment analysts at HC Wainwright decreased their Q2 2024 EPS estimates for X4 Pharmaceuticals in a research note issued to investors on Tuesday, April 30th. HC Wainwright analyst S. Ramakanth now forecasts that the company will earn ($0.24) per share for the quarter, down from their prior estimate of ($0.20). HC Wainwright has a “Buy” rating and a $5.00 price target on the stock. The consensus estimate for X4 Pharmaceuticals’ current full-year earnings is ($0.51) per share. HC Wainwright also issued estimates for X4 Pharmaceuticals’ Q4 2024 earnings at ($0.16) EPS, FY2024 earnings at ($0.76) EPS, Q3 2025 earnings at ($0.08) EPS, Q4 2025 earnings at ($0.05) EPS and FY2025 earnings at ($0.41) EPS.

X4 Pharmaceuticals Stock Up 6.5 %

X4 Pharmaceuticals stock opened at $1.15 on Thursday. The firm has a market cap of $193.13 million, a price-to-earnings ratio of -1.92 and a beta of 0.51. The company has a debt-to-equity ratio of 1.07, a current ratio of 5.34 and a quick ratio of 5.34. X4 Pharmaceuticals has a fifty-two week low of $0.57 and a fifty-two week high of $2.58. The firm has a fifty day moving average price of $1.16 and a two-hundred day moving average price of $0.93.

X4 Pharmaceuticals (NASDAQ:XFOR) last issued its quarterly earnings data on Thursday, March 21st. The company reported ($0.10) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.05.

Insiders Place Their Bets

In other X4 Pharmaceuticals news, CFO Adam S. Mostafa sold 27,721 shares of the business’s stock in a transaction on Monday, February 12th. The shares were sold at an average price of $1.01, for a total transaction of $27,998.21. Following the completion of the transaction, the chief financial officer now owns 52,500 shares of the company’s stock, valued at approximately $53,025. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, CFO Adam S. Mostafa sold 27,721 shares of the company’s stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $1.01, for a total transaction of $27,998.21. Following the completion of the transaction, the chief financial officer now owns 52,500 shares of the company’s stock, valued at $53,025. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Paula Ragan sold 49,678 shares of the company’s stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $0.88, for a total transaction of $43,716.64. Following the transaction, the chief executive officer now directly owns 765,068 shares of the company’s stock, valued at approximately $673,259.84. The disclosure for this sale can be found here. Insiders sold a total of 185,708 shares of company stock valued at $170,428 in the last quarter. Insiders own 1.08% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Kingdon Capital Management L.L.C. raised its position in X4 Pharmaceuticals by 76.0% in the fourth quarter. Kingdon Capital Management L.L.C. now owns 3,473,683 shares of the company’s stock worth $2,913,000 after purchasing an additional 1,500,000 shares in the last quarter. Bain Capital Life Sciences Investors LLC raised its position in X4 Pharmaceuticals by 6.0% in the fourth quarter. Bain Capital Life Sciences Investors LLC now owns 16,915,784 shares of the company’s stock worth $14,184,000 after purchasing an additional 955,196 shares in the last quarter. Stonepine Capital Management LLC raised its position in X4 Pharmaceuticals by 14.5% in the third quarter. Stonepine Capital Management LLC now owns 5,273,685 shares of the company’s stock worth $5,748,000 after purchasing an additional 668,422 shares in the last quarter. GSA Capital Partners LLP acquired a new position in X4 Pharmaceuticals in the third quarter worth about $678,000. Finally, Barclays PLC raised its position in X4 Pharmaceuticals by 334.8% in the third quarter. Barclays PLC now owns 382,134 shares of the company’s stock worth $417,000 after purchasing an additional 294,255 shares in the last quarter. Institutional investors and hedge funds own 72.03% of the company’s stock.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.